	US 12,296,051 B2
	Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
Harsh Mehta, Randolph, NJ (US)
Assigned to Bayer HealthCare LLC, Whippany, NJ (US)
Filed by Bayer HealthCare LLC, Whippany, NJ (US)
Filed on Jun. 22, 2023, as Appl. No. 18/213,143.
Application 18/213,143 is a continuation of application No. 17/524,522, filed on Nov. 11, 2021, granted, now 11,857,684.
Claims priority of provisional application 63/113,298, filed on Nov. 13, 2020.
Prior Publication US 2024/0091158 A1, Mar. 21, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A61J 3/10 (2006.01); A61K 9/24 (2006.01); A61K 31/137 (2006.01); A61K 31/616 (2006.01)

CPC A61K 9/209 (2013.01) [A61J 3/10 (2013.01); A61K 31/137 (2013.01); A61K 31/616 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01)]

21 Claims

1. A bilayer tablet, comprising:

an acetylsalicylic acid layer comprising:

granules comprising intragranular acetylsalicylic acid and intragranular sodium carbonate; and

extragranular acetylsalicylic acid; and

an active pharmaceutical ingredient layer comprising:

an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof; and

sodium carbonate.